Recent Articles

July 6, 2015 3:03 pm
Yogesh Soneji, Principal, Trinity Partners
Innovation in healthcare is at a record level – but so is its cost.  The number of novel drugs approved between 2011 and 2015 was more than 40 percent higher than in the previous five years. With certain therapies approaching a $1 million-plus price tag, it’s time to ask: will innovation eventually get stifled or can companies reimagine their business models? Read more...
July 6, 2015 12:38 pm
Ryan Bushey, Associate Editor
An estimated 5,000 to 10,000 people suffer from this condition worldwide with it typically appearing in early childhood. Read more...
July 1, 2015 3:41 pm
Heather Leach, Ph.D., Immunology and Neurology Analyst, GlobalData
The most promising products are Xadago and Rytary for early and advanced patients, and Acorda’s CVT-301 for advanced patients. Read more...
June 30, 2015 4:39 pm
Ryan Bushey, Associate Editor
The company is treading in establishing the exact cost per pill. Read more...
June 30, 2015 10:04 am
Kelly L. Lightfoot, Esq., Fuerst Ittleman David & Joseph
The first step in assessing how a HCT/P will be regulated by the FDA, and whether the resulting product will require an expensive and lengthy approval process, is determining if the HCT/P is more than minimally manipulated. Read more...
June 30, 2015 8:28 am
Sumith Ladda, Analyst, GBI Research
The 30 percent to 50 percent reduction in biosimilar prices compared with branded biologics could lead to considerable savings in healthcare expenditure. Read more...
June 29, 2015 9:18 am
Cynthia Fox, Science Editor
A new blood test identified pancreatic cancer with 100 percent accuracy in 250 of 250 patients, said a recent report in Nature. The test found pancreatic exosomes in blood via the biomarker GPC1. It distinguished early-stage cancer from late-stage cancer—with zero false positives/negatives. It predicted survival. Read more...
June 29, 2015 2:38 pm
Ryan Bushey, Associate Editor
The organization is calling for the European Union to take emergency action. Read more...
June 26, 2015 1:35 pm
Ryan Bushey, Associate Editor
The CEO of Allergan discussed the future of his company after the completion of the Actavis merger. Read more...
June 25, 2015 3:27 pm
Adam Dion, MS, Senior Industry Analyst, GlobalData
Nearly $1.5 billion was raised in the gene therapy arena from 2014 to 2015. Read more...
Subscribe to Drug Discovery & Development